These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 8444668)

  • 41. Efficacy of ampicillin plus a beta-lactamase inhibitor (CP-45,899) in experimental endocarditis due to Staphylococcus aureus.
    Washburn RG; Durack DT
    J Infect Dis; 1981 Sep; 144(3):237-43. PubMed ID: 6268715
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Enterococcal endocarditis revisited.
    Pericás JM; Zboromyrska Y; Cervera C; Castañeda X; Almela M; Garcia-de-la-Maria C; Mestres C; Falces C; Quintana E; Ninot S; Llopis J; Marco F; Moreno A; Miró JM
    Future Microbiol; 2015; 10(7):1215-40. PubMed ID: 26118390
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Use of ampicillin-sulbactam for treatment of experimental meningitis caused by a beta-lactamase-producing strain of Escherichia coli K-1.
    Guerra-Romero L; Kennedy SL; Fournier MA; Tureen JH; Täuber MG
    Antimicrob Agents Chemother; 1991 Oct; 35(10):2037-41. PubMed ID: 1759824
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Ampicillin-sulbactam.
    Dajani AS
    Pediatr Ann; 1993 Mar; 22(3):197-200. PubMed ID: 8464651
    [No Abstract]   [Full Text] [Related]  

  • 45. Susceptibility and bactericidal activity studies of four beta-lactamase-producing enterococci.
    Patterson JE; Zervos MJ
    Antimicrob Agents Chemother; 1989 Feb; 33(2):251-3. PubMed ID: 2497706
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Continuous intravenous versus intermittent ampicillin therapy of experimental endocarditis caused by aminoglycoside-resistant enterococci.
    Hellinger WC; Rouse MS; Rabadan PM; Henry NK; Steckelberg JM; Wilson WR
    Antimicrob Agents Chemother; 1992 Jun; 36(6):1272-5. PubMed ID: 1416826
    [TBL] [Abstract][Full Text] [Related]  

  • 47. In vitro activity of sulbactam/ampicillin against ampicillin-resistant, beta-lactamase-producing bacteria isolated in Italian hospitals.
    Varaldo PE; Ripa S; Nicoletti G; Covelli I; Satta G; Carlone N; Fontana R
    Chemotherapy; 1990; 36(2):141-6. PubMed ID: 2178890
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy of sulbactam in an in vitro model of mixed aerobic/anaerobic infections.
    Heizmann WR; Heilmann F; Egeler B; Werner H
    Infection; 1990; 18(2):117-21. PubMed ID: 2332245
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Critical importance of in vivo amoxicillin and cefotaxime concentrations for synergy in treatment of experimental Enterococcus faecalis endocarditis.
    Join-Lambert O; Mainardi JL; Cuvelier C; Dautrey S; Farinotti R; Fantin B; Carbon C
    Antimicrob Agents Chemother; 1998 Feb; 42(2):468-70. PubMed ID: 9527811
    [TBL] [Abstract][Full Text] [Related]  

  • 50. In vivo activity of the combination of daptomycin and fosfomycin compared with daptomycin alone against a strain of Enterococcus faecalis with high-level gentamicin resistance in the rat endocarditis model.
    Rice LB; Eliopoulos CT; Yao JD; Eliopoulos GM; Moellering RC
    Diagn Microbiol Infect Dis; 1992 Feb; 15(2):173-6. PubMed ID: 1315234
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Enterococci as uropathogens. Frequency of isolation and sensitivity to antibacterial agents].
    Guirguitzova B; Chankova D; Zozikov B; Minkov N
    Ann Urol (Paris); 1998; 32(1):15-9. PubMed ID: 9559070
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy of ampicillin-sulbactam is not dependent upon maintenance of a critical ratio between components: sulbactam pharmacokinetics in pharmacodynamic interactions.
    Alexov M; Lister PD; Sanders CC
    Antimicrob Agents Chemother; 1996 Nov; 40(11):2468-77. PubMed ID: 8913448
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Restricting the use of ampicillin-sulbactam.
    Zavascki AP; Sandri AM
    J Hosp Infect; 2004 Feb; 56(2):165-6. PubMed ID: 15019231
    [No Abstract]   [Full Text] [Related]  

  • 54. Differential in vitro susceptibility to ampicillin/ceftriaxone combination therapy among Enterococcus faecalis infective endocarditis clinical isolates.
    Westbrook KJ; Chilambi GS; Stellfox ME; Nordstrom HR; Li Y; Iovleva A; Shah NH; Jones CE; Kline EG; Squires KM; Miller WR; Tran TT; Arias CA; Doi Y; Shields RK; Van Tyne D
    J Antimicrob Chemother; 2024 Apr; 79(4):801-809. PubMed ID: 38334390
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Ceftriaxone-sulbactam combination in rabbit endocarditis caused by a strain of Klebsiella pneumoniae producing extended-broad-spectrum TEM-3 beta-lactamase.
    Caron F; Gutmann L; Bure A; Pangon B; Vallois JM; Pechinot A; Carbon C
    Antimicrob Agents Chemother; 1990 Nov; 34(11):2070-4. PubMed ID: 2073099
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A Review of Combination Antimicrobial Therapy for Enterococcus faecalis Bloodstream Infections and Infective Endocarditis.
    Beganovic M; Luther MK; Rice LB; Arias CA; Rybak MJ; LaPlante KL
    Clin Infect Dis; 2018 Jul; 67(2):303-309. PubMed ID: 29390132
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparative evaluation of the in vitro activity of three combinations of beta-lactams with beta-lactamase inhibitors: piperacillin/tazobactam, ticarcillin/clavulanic acid and ampicillin/sulbactam.
    Sader HS; Tosin I; Sejas L; Miranda E
    Braz J Infect Dis; 2000 Feb; 4(1):22-8. PubMed ID: 10788842
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A new pharmacodynamic approach to study antibiotic combinations against enterococci in vivo: Application to ampicillin plus ceftriaxone.
    Jimenez-Toro I; Rodriguez CA; Zuluaga AF; Otalvaro JD; Vesga O
    PLoS One; 2020; 15(12):e0243365. PubMed ID: 33290425
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Activity of sulbactam combinations against Escherichia coli isolates with known amounts of TEM-1 beta-lactamase.
    Livermore DM
    J Antimicrob Chemother; 1992 Feb; 29(2):222-4. PubMed ID: 1506339
    [No Abstract]   [Full Text] [Related]  

  • 60. Single-agent therapy for acute pelvic inflammatory disease: sulbactam/ampicillin versus cefoxitin.
    Hemsell DL; Bawdon RE; Hemsell PG; Nobles BJ; Heard MC
    J Int Med Res; 1990; 18 Suppl 4():85D-89D. PubMed ID: 2282973
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.